Longeveron (NASDAQ:LGVN – Get Free Report) and Sera Prognostics (NASDAQ:SERA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Profitability
This table compares Longeveron and Sera Prognostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
Analyst Ratings
This is a breakdown of recent recommendations for Longeveron and Sera Prognostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
Institutional and Insider Ownership
10.0% of Longeveron shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Longeveron and Sera Prognostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.20 million | 6.86 | -$22.70 million | ($9.90) | -0.26 |
| Sera Prognostics | $80,000.00 | 1,030.63 | -$31.93 million | ($0.67) | -3.12 |
Longeveron has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Longeveron has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Summary
Sera Prognostics beats Longeveron on 9 of the 14 factors compared between the two stocks.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
